Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06191393 · ClinicalTrials.gov registry record · NA
SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings
A NA study, sponsored by Aptitude Medical Systems.
- Completed
- Registry status
- NA
- Development phase
- 614
- Enrollment target
NCT06191393 is a NA study that has completed, run by Aptitude Medical Systems. The registered enrollment target is 614 participants.
The verdict
NCT06191393, a NA study, has completed, sponsored by Aptitude Medical Systems.
- COMPLETED
- Registry status
- NA
- Development phase
- 614 participants
- Enrollment target
Study Summary
The Metrix COVID/Flu Test will be evaluated for use in Point-of-Care and Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein. The study will take place in simulated home environments which will be set up within or near active clinical settings (e.g., urgent care facilities). This will be a prospective study conducted at three or more investigational sites located within the United States for the clinical validation of the Metrix COVID/Flu Test for the differential detection of SARS-CoV-2, Influenza A, and Influenza B in AN swab or saliva samples. Additional sites may be added to the study in order to meet minimum subject/sample enrollment requirements and geographic prevalence of respiratory virus infections. One or more investigational sites outside of the US (at which participants are required to be fluent in English) may also be included in the study depending on enrollment needs and geographical/seasonal prevalence of respiratory virus infections. Comparator testing will be performed to determine the infection status of each sample for comparison to results generated by the candidate test. The primary comparator for the study will be an FDA-cleared assay for the detection of SARS-CoV-2, Flu A, and/or Flu B.
Interventions
- DIAGNOSTIC_TEST Aptitude Medical Systems Metrix COVID/Flu Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 614 participants |
| Start Date | 2023-11-20 |
| Est. Completion | 2025-03-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06191393
The ClinicalTrials.gov registry entry for NCT06191393 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 614 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aptitude Medical Systems, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aptitude Medical Systems Metrix COVID/Flu Test is the first listed.
NCT06191393 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06191393 about?
NCT06191393 is a clinical study titled "SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings". The Metrix COVID/Flu Test will be evaluated for use in Point-of-Care and Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein. The study will take place in simulated home environments which will be set up within or near active clinical settings (...
What is the current status of trial NCT06191393?
This trial is currently completed. It is a NA study. The enrollment target is 614 participants. The study started on 2023-11-20. Estimated completion is 2025-03-11.
What interventions are being tested in trial NCT06191393?
The interventions under investigation include: Aptitude Medical Systems Metrix COVID/Flu Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06191393?
This trial is sponsored by Aptitude Medical Systems, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.